Methods and compositions for the treatment and prevention of lung disease
Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.
1 . A composition for the treatment or prevention of alveolar destruction in a mammal comprising a pharmaceutically effective amount of an RARγ agonist having specific RAR modulating activity, wherein said RARα agonist is not an agonist of RARβ.
2 . The composition of claim 1 wherein said RARγ agonist is not specific to RARβ.
3 . The composition of claim 1 wherein said RARγ agonist is not specific to RARα.
4 . The composition of claim 1 wherein said RARγ agonist is not specific to RARβ or RARα.
5 . The composition of claim 1 wherein said composition further comprises said RARγ agonist in dissolved form.
6 . The composition of claim 5 wherein said RARγ agonist is not specific to RARβ.
7 . The composition of claim 5 wherein said RARγ agonist is not specific to RARα.
8 . The composition of claim 5 wherein said RARγ agonist is not specific to RARβ or RARα.
9 . An aerosol for pulmonary delivery of a pharmaceutical composition, said pharmaceutical composition comprising an RARγ agonist having specific RAR modulating activity, wherein said RARα agonist is not an agonist of RARβ.
10 . The aerosol of claim 9 wherein said RARγ agonist is not specific to RARβ.
11 . The aerosol of claim 9 wherein said RARγ agonist is not specific to RARα.
12 . The aerosol of claim 9 wherein said RARγ agonist is not specific to RARβ or RARα.
13 . A method for the treatment or prevention of alveolar destruction in a mammal comprising the step of administering to said mammal a therapeutically effective amount of an RAR-specific RARγ agonist, wherein said RARα agonist is not an agonist of RARβ.
14 . The method of claim 13 wherein said RARγ agonist is not specific to RARβ.
15 . The method of claim 13 wherein said RARγ agonist is not specific to RARα.
16 . The method of claim 13 wherein said RARγ agonist is not specific to RARβ or RARα.
17 . The method of claim 13 , wherein said composition is administered in the form of an inhalant.
18 . The method of claim 17 wherein said RARγ agonist is not specific to RARβ.
19 . The method of claim 17 wherein said RARγ agonist is not specific to RARα.
20 . The method of claim 17 wherein said RARγ agonist is not specific to RARβ or RARα.
21 . A method to increase the gas-exchange surface area of a mammalian lung in a mammal in need thereof comprising the step of administering to said mammal a therapeutically effective amount of an RARγ agonist having specific RAR modulating activity, wherein said RARα agonist is not an agonist of RARβ.
22 . The method of claim 21 wherein said RARγ agonist, is not specific to RARβ.
23 . The method of claim 21 wherein said RARγ agonist is not specific to RARα.
24 . The method of claim 21 wherein said RARγ agonist is not specific to RARα or RARα.
25 . The method of claim 21 , wherein said composition is administered in the form of an inhalant.
26 . The method of claim 25 wherein said RARγ agonist is not specific to RARβ.
27 . The method of claim 25 wherein said RARγ agonist is not specific to RARα.
28 . The method of claim 25 wherein said RARγ agonist is not specific to RARβ or RARα.